admin

Federal Minister for Commerce Jam Kamal Khan chaired a high-level review, directing Foreign Trade Wings to formulate country-specific plans prioritizing pharmaceutical exports. The initiative focuses on resolving market-access barriers, improving trade logistics, and leveraging international trade missions to boost Pakistani pharma globally.

Pakistan is moving toward WHO Maturity Level-3 accreditation by April 2027—a landmark step announced by Health Minister Syed Mustafa Kamal. PPMA fully supports DRAP and the Ministry of Health in unlocking new international trade opportunities and setting global regulatory standards.

The Cabinet Committee for Drug Pricing, chaired by Finance Minister Muhammad Aurangzeb, has approved Maximum Retail Prices (MRPs) for 52 new advanced molecules targeting Cancer, Diabetes, and Hypertension.This major milestone brings the total approved essential drugs to 87 in just 4 months. Official notification will pave the way for local production and unlock strong potential

PPMA presented the pharmaceutical industry’s perspective on key sector issues, including the deregulation of non-essential medicines. The meeting was presided over by Senator Aamir Chishti, Chairman of the Standing Committee.

DRAP has officially issued draft amendments regarding the Drugs Labelling and Packing Rules and is requesting feedback from stakeholders. We urge all pharmaceutical manufacturers to review the draft to support:✅ Supply-chain software integration✅ Regulatory compliance✅ Patient safetyStay proactive and share your valuable inputs today.

The Pak-China Business Conference concluded with $1.4 Billion in total investment commitments, including 42 final-day deals! 🚀 This historic partnership focuses on: Local Active Pharmaceutical Ingredient (API) Manufacturing Vaccine Production Advanced Medical Equipment These commitments mark a pivotal step toward reducing reliance on imports, boosting exports, and strengthening national healthcare self-reliance.

Tomorrow in Islamabad, the Pakistan–China B2B Investment Conference kicks off, bringing together over 450+ firms to forge the Sino-Pak Pharma Alliance. With the support of DRAP, BOI, and SIFC, this summit isn’t just about discussions—it is about immediate, project-driven results. Dedicated on-site regulatory desks will be active to instantly fast-track licensing and joint venture approvals,

A new era of healthcare transparency begins. The Drug Regulatory Authority of Pakistan (DRAP) has established critical regulatory timelines to safeguard public health: The Pakistan Pharmaceutical Manufacturers Association (PPMA) strongly welcomes these landmark regulatory milestones, standing united with DRAP in this definitive victory for national patient safety and pharmaceutical innovation.

Under the newly announced Federal Budget 2026-27, the government has officially exempted customs duties on critical cancer-related Active Pharmaceutical Ingredients (APIs). This public health relief will significantly reduce manufacturing costs and make life-saving cancer treatments much more affordable across Pakistan.